India: Medical Device Monitor: March 2017

Last Updated: 20 April 2017
Article by SKP  


The global medical devices market is valued at USD 342.39 billion, out of which India's market accounts for a meagre 1.3% of the total value. The Government of India announced a revised Foreign Direct Investment (FDI) policy for the sector in January 2015 in which foreign investment up to 100% was allowed under the automatic route for both greenfield and brownfield investments. The Reserve Bank of India (RBI) has been mandated by the Ministry of Finance's (MoF's) Financial Intelligence Unit (FIU) to investigate all investments made in the medical devices sector post January 2015 through the automatic route.

The definition of medical devices, for FDI, is the definition as proposed in the Drugs and Cosmetics (Amendment) Bill, 2013. However, the government withdrew this Bill from the Rajya Sabha (Upper House) in June 2016 and released the new Medical Device Rules, 2017 for the sector which will be enforced from 1 January 2018. The Ministry of Health and Family Welfare (MoHFW) is working on a separate legislation to regulate medical devices. The withdrawal of the amendment bill has led to a loophole in the policy as the draft legislation is yet to be enforced and has given the FIU a reason to believe that there could be misrepresentations and companies might invest through the automatic route, even if they are not entitled to do so.

The FIU made these observations post the proposed investment by BioMérieux, a French biotechnology firm, in RAS Lifesciences Private Limited whereby the increase in stake from 60% to 70% came to light.1 Based on the application made to the RBI, BioMérieux believes that it does not need to take approval from the Foreign Investment Promotion Board (FIPB) as the investment was proposed post the withdrawal of the FIPB nod by the government. The RBI agreed with the company and permitted the investment.

Before January 2015, the policy governing FDI in the medical devices sector had three major conditions which were:

  • The foreign investor needs to sign a non-compete clause except with the approval of the FIPB;
  • A certificate along with the FIPB application by the investor and investee is required; and
  • The right to incorporate appropriate conditions for FDI in brownfield investments.

The gap in the policy has the following consequences:

  • After the January 2015 FDI policy announcement, for any foreign investment to qualify under the automatic route, the activity of the company should be confined to manufacturing medical devices and should exclude pharmaceuticals or brownfield pharmaceutical acquisitions.
  • As there is ambiguity over the rules, companies may avail the automatic route, deliberately or otherwise, which they may not be entitled to as the definition under the FDI policy is different from the one effective by law.

To address this issue and avoid hampering any investment while keeping the law as clear as possible, the FIU reached out to the Department of Industrial Policy and Promotion (DIPP) to revisit the FDI policy in consultation with the DoP. The DIPP may issue a notification stating that the definition of medical devices under the FDI policy released in January 2015 will be the definition as prescribed in the Drugs and Cosmetics Act, 1940 and any amendment made to the said act from time to time.2

TÜV SÜD, a German testing and certification company, recently announced a host of different services for medical device manufacturers in India. The aim of these services is to give Indian products global acceptability and exposure, and to provide Indian manufacturers the opportunity to upgrade their products and processes.3


The government of India, over the period of the past 12 months, has been very active on reforms for the medical devices sector. With the introduction of new rules, the government for the first time has defined medical devices separately and has brought the rules up to global standards. The government also took action on the long-standing complaint of overcharging on stents by capping the price, while the consumers are rejoicing the industry is not.

Medical Devices Rules

The ministry released the first draft of rules in July 2016 and post consultation with the industry and stakeholders released the second draft in October 2016. In January 2017, the MoHFW notified the Medical Devices Rules, 20174 and announced that they would be effective from 1 January 2018, thereby providing time for players to adapt to the new rules.5 The rules have been framed to conform to the framework laid down by the Global Harmonization Task Force (GHTF) for medical devices. The rules aim to bring the Indian medical devices industry on par with global standards and have been customised while keeping the Indian context in mind. The major changes made in the rules are:

Definition of medical devices

The 2017 rules define medical devices as follows:

  • Specific devices intended for internal or external use in the diagnosis, treatment, mitigation or prevention of diseases or disorders in human beings or animals which are notified by the government from time to time under the Act. Some categories of devices have already been notified by the government.
  • Specific substances intended to affect the structure or any function of the human body which are not notified by the government. At present, the substances notified are mechanical contraceptives (e.g. condoms, intra-uterine devices, tubal rings) and disinfectants.
  • Surgical dressings, surgical bandages, surgical staples, surgical sutures, ligatures, blood and blood component collection bags with or without anticoagulant.
  • Substances used for in-vitro diagnosis.
  • All substances intended to be used for or in the diagnosis, treatment, mitigation or prevention of any disease or disorder in human beings or animals.

The rules explicitly mention that all devices are regulated which are covered by the definition above, however, the Drugs and Cosmetics Act also include medical devices as part of the definition of the 'drug' and since it has not been amended, the rules will apply to all medical devices. Fortunately, the rules provide clarity and states that in case of confusion/contradictions between the 2017 rules and the Drugs and Cosmetics Act, the 2017 rules will prevail.

Classification of devices

The new rules introduce a rational and scientific approach to the classification, segmenting products based on the risk these devices may pose to human beings. The devices with the lowest risk are class A devices, devices with moderate risk are class B devices, devices with moderately high risk are class C devices and devices with high risk are class D devices. Class A products will not be brought under the purview of any regulation. Class A and class B products consists of X-ray machines, computerised tomography machines, magnetic resonance imaging machines, etc. whereas class C and class D products consists of stents and other implantable devices.

Quality management

With the intention to ensure quality and add quality credence to the Indian medical devices, the rules envision a system wherein third parties can conduct an assessment and certify quality management systems of Class A and B device manufacturers. These certifying bodies have to be accredited by the National Accreditation Board for Certification Bodies (NABCB) to prove their competence with regard to the capability of their human resource. The rules also mention that these third-party bodies can provide assistance to the NABCB for regulating Class C and Class D products. The rules aim to encourage self-certification and hence allow Class A manufacturers to obtain manufacturing licenses before the audit of the facility. However, after getting the approval, an audit has to be conducted by an NABCB accredited body. The rules have empowered state licensing authorities to allocate licenses for Class A and Class B manufacturers. However, the Central Licensing Authority (CLA) will regulate licenses for Class C and Class D manufacturers. The CLA can ask for assistance from experts and other notified bodies on a case to case basis.

Clinical trials

The new rules have separate provisions for the clinical trials of medical devices and these trials will be referred to as clinical investigations. The provisions have eliminated the four-phase stringent trial norms that are applicable for pharmaceuticals and have introduced a two-phase process. Phase one will involve conducting a pilot study on a small focus group to prove the safety and performance. Phase two will be conducted on a larger group. The Central Drugs Standard Control Organization (CDSCO) will regulate the trials of investigative medical devices. Separate provisions for medical management and compensation for the subjects of the trials have been introduced to achieve patient safety. The rules have provided for compensation of up to INR 800,000 for people affected by an adverse trial.

Product standards:

Earlier, there was no clarity of product standards to be followed by medical device manufacturers and there was constant confusion. Medical device manufacturers earlier were in a dilemma as to which BIS (Bureau of Indian Standards) standard to follow for the products. However, the new rules aim to clarify the same and have listed down three standards which are to be followed in the same order and are as follows:

  • A standard notified by the Central government for the medical device specifically or which has been laid down by the BIS or;
  • Where (a) is absent, to a standard laid down by International Organization for Standardization (ISO) or the International Electrotechnical Commission (IEC); or
  • Where both (a) and (b) are absent, the validated manufacturer's standard.


The new rules have eliminated the need for constant re-approval of manufacturing licenses. The licenses have been given indefinite validity, unless the license is suspended, terminated or has been surrendered by the manufacturer. Also, the rules have eliminated the need for applying for a registration certificate at the time of registrating as a foreign manufacturer as well as the need of an import license. Now, the rules specify that a foreign manufacturer only has to appoint an agent in India and then apply for an import license thereby decreasing the time taken to obtain a license. For making the process of approval easy and user-friendly, the entire process can be done online. The rules have capped the shelf-life of medical devices at five years from the date of manufacturing. The rules allow for this shelf-life to be extended provided sufficient evidence is provided by the manufacturer to the CLA to justify the extension. Henceforth, from the applications stage to getting the approval/permission, the process will be online. Also, the rules mention that the National Accreditation Board for Testing and Calibration Laboratories (NABL) along with other agencies will establish laboratories for testing medical devices.

Price ceiling on stents

Coronary stents are used for clearing blockages in coronary arteries. With changing lifestyles, improving access and incomes, and the growth in incidence of chronic diseases like IHD, the number of stent procedures in India has increased significantly and strong growth continues. There are a variety of stents that are sold in the market like bare metal stents, drug-eluting stents, including several newer generation stents. To provide a better perspective, in 2010, approximately 145,000 stent insertion procedures were carried out and in 2015, the number increased to approximately 345,000. With the increase in the number of procedures, the prices of these stents also skyrocketed at the patient level. The government bodies felt that patients and families in general are not able to understand this category well and have been exploited. A report from the National Pharmaceutical Pricing Authority (NPPA) illustrated an analysis of foreign made stents and how they flow through the distribution chain. The report found out that there were profits made by various stakeholders which the report termed as unreasonable. The variance between the landed cost of imported stents and the Maximum Retail Price (MRP) ranged between 300% and 1200%. These margins were inflating the cost of healthcare services drastically because of which these services were unaffordable for many patients.6

The DoP issued a notification in December 2016 stating that a price cap will be imposed on coronary stents so that exploitative pricing can be stopped. The notification would allow the NPPA to ascertain the maximum prices of stents. All coronary, bare metal, drug-eluting stents and subtypes stents such as bioresorbable vascular scaffolds and biodegradable stents are covered under the notification.

By mid-February, the NPPA came out with a formula to regulate the prices of different cardiac stents under two categories: drug-eluting stents and bare metal stents. Accordingly, the NPPA issued a notification stating that the ceiling price of drug-eluting stents and bioresorbable stents will be fixed at INR 29,600 per unit and bare metal stents at INR 7,260 per unit. Para 24 (4) of the Drug Price Control Order (DPCO), 2013 states, "Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same". After this notification, hospitals have to prepare separate bills for stents (and will not be able to include them in overall procedure/package prices).

The industry has, in general, vigorously opposed the cap. AdvaMed, an international group of device makers, expressed its disappointment with the price cap and said that all stakeholder representations submitted to explain the differentiation between various kinds of stents have been disregarded. The group also suggested that there is a possibility of this step blocking innovation and hampering the sector in the long-run. AiMed, a body representing domestic stent manufacturers, believes that the cap is too harsh and will adversely effect the industry. They believe that the caps need to be reasonable and should allow a smooth transition, and the order, being effective immediately, is not viable.

Doctors have a mixed view on the notification. Dr Vivek Jawali7, chief cardiothoracic and vascular surgeon of Fortis Hospital, believes that the regulation will lead to cheap dumping from China and Canada and FDA approved stents will eventually be withdrawn from the market as they all have been clubbed in a single segment. However, certain hospitals have welcomed the move and will pass the benefit on to the patients. Health experts feel that the average landing price may not exceed INR 17,000 and hence, a price of INR 29,000 still leaves room for profit margins. However, these margins will not sustain R&D and innovation.

There is a possibility that device makers can approach the NPPA to claim higher prices post proving that their technology is better than the existing devices as per the pharmaceutical industry practice.8 However, that might be easier said then done, as a committee of doctors for accessing the essentiality of stents found that there is no clinical data available on deaths or heart attacks on the available drug-eluting stents. It also noted that superiority of bio-absorbable stents is yet to be demonstrated.9 In fact, a study published in the Lancet journal in November 2016 found that bio-absorbable stents, which are touted by many as technologically advanced, posed a higher risk of artery blockage. Thus, it will be critical for the stent makers to prove differentiation in the product on account of technical innovation.

While there have been positive policy initiatives for the industry, the introduction of price control on some devices, and more importantly, the method in which prices are being fixed and regulated are a major hurdle for the industry and have left many participants concerned and confused. In the case of coronary stents, which is the first category of products for which price control has been announced, the following gaps are worrying:

  • No serious and rigorous assessment of the medical technology differences between different kinds of stents and the impact of the same appears to have been done.
  • A better understanding of the price build-up through the entire chain, from supplier to consumer, and how it would affect various stakeholders is needed in this industry. Also, a better assessment should have been made of what margins are required and reasonable through the supply/value chain.
  • Other options to widen access to the underprivileged with lower cost devices and procedures should have been evaluated.
  • More thought as to how to encourage innovation in this industry, where product and technology life cycles are short, is required. It is evident that there needs to be a thorough and proper study conducted by a premier institute like the Indian Council for Medical Research and guide the DoP and NPPA on the appropriate structure. The MTAB10 (Medical Technology Assessment Board), which has been announced but yet to be notified, could be tasked to bring in adequate process and rigour into the technology assessment.

The industry believes that NPPA arrived at the prices in haste and should have conducted more diligence in capping the prices. The NPPA on the other hand believes that the action was due and the public at large should be benefitted with immediate effect. It is clear that while the NPPA's intention is legitimate, the approach to implementation should have been different.

To view the full article click here












The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
23 Jan 2018, Webinar, Mumbai, India

Join us for our webinar for insights on how the Indian government could possibly reform, perform and transform the economy through Union Budget 2018.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions